ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

RANI Rani Therapeutics Holdings Inc

7.52
0.37 (5.17%)
Fuera de horario
Última actualización: 15:05:07
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Rani Therapeutics Holdings Inc RANI NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.37 5.17% 7.52 15:05:07
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
7.08 6.90 7.7199 7.52 7.15
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/5/202415:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202415:05GLOBERani Therapeutics Reports First Quarter 2024 Financial..
06/5/202415:04EDGAR2Form 8-K - Current report
20/3/202415:05GLOBERani Therapeutics Reports Fourth Quarter and Full Year 2023..
15/3/202415:05GLOBERani Therapeutics to Report Fourth Quarter and Full Year..
05/2/202407:10EDGAR2Form 8-K - Current report
05/2/202407:00GLOBERani Therapeutics Announces Positive Topline Results from..
19/12/202315:06EDGAR2Form 8-K - Current report
19/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202307:05EDGAR2Form 8-K - Current report
14/12/202307:00GLOBERani Therapeutics Announces Preclinical Pharmacodynamic Data..
07/12/202316:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202307:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202307:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:10EDGAR2Form 8-K - Current report
08/11/202315:05GLOBERani Therapeutics Reports Third Quarter 2023 Financial..
01/11/202315:05GLOBERani Therapeutics Announces Strategic Program..
01/11/202315:04EDGAR2Form 8-K - Current report
25/10/202307:03EDGAR2Form 8-K - Current report
25/10/202307:00GLOBEThe RaniPill® Capsule, Rani Therapeutics’ Oral Delivery..
19/10/202315:05GLOBERani Therapeutics Announces Successful Oral Delivery of..
12/10/202315:05GLOBERani Therapeutics to Present Abstract on RT-102 at the 2023..
18/9/202307:00GLOBERani Therapeutics Initiates Phase 1 Study of RT-111..
07/9/202316:04EDGAR2Form 8-K - Current report
07/9/202315:05GLOBERani Therapeutics Announces Successful Drug Delivery of..
06/9/202307:00GLOBERani Therapeutics to Participate in September Investor..
11/8/202315:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202315:05GLOBERani Therapeutics Reports Second Quarter 2023 Financial..
08/8/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202315:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/8/202315:05GLOBERani Therapeutics to Participate in August Investor..
21/6/202307:00GLOBERani Therapeutics’ Presentation On Oral Delivery of PTH for..
08/6/202307:00GLOBERani Therapeutics Announces Acceptance of Late-Breaking..
05/6/202307:00GLOBERani Therapeutics and Celltrion Expand Partnership to..
01/6/202307:00GLOBERani Therapeutics to Present at the Jefferies Healthcare..
31/5/202307:00GLOBERani Therapeutics Announces Acceptance of Three Abstracts..
24/5/202307:00GLOBERani Therapeutics Appoints Kate McKinley as Chief Business..
10/5/202315:05GLOBERani Therapeutics Reports First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock